Scientists create artificial ovary giving hope to infertile women
A synthetic organ – made out of the woman's own tissue – could be transplanted into a female left infertile due to medical treatment. She could then go on to produce eggs naturally.
Publication date: Available online 3 November 2018Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Marc Kanbar, Francesca di Michele, Christine WynsAbstractTransplantation of own cryostored spermatogonial stem cells (SSCs) is a promising technique for fertility restoration when the SSC pool has been depleted.In this regard, cryopreservation of pre-pubertal testicular tissue or SSCs suspensions before gonadotoxic therapies is ethically accepted and increasingly proposed.SSC transplantation has also been considered to treat other causes of infertility relying on the possibility of propagat...
Objective: The better part of this decade has been path breaking in the field of Infertility for having tackled unanswered questions of Absolute Uterine factor infertility. Uterine transplant has been the harbinger of joy to various couples worldwide who have faced absolute uterine factor infertility and are unwilling or unable to opt for adoption and surrogacy. With Minimally invasive gynecology already at its peak, Uterine transplant has helped achieve another feat in an already extended spectrum of treatment and cure.
This article is protected by copyright. All rights reserved. PMID: 30276952 [PubMed - as supplied by publisher]
This study summarizes ovarian tissue cryopreservation and transplantation indications, procedures, their efficacy and main results and proposes different strategies to improve this strategy. Although the main focus of this study is on ovarian tissue cryopreservation and transplantation as a strategy to restore fertility, we believe that it is also important to discuss other applications for this approach.
Purpose of review The current review gives an updated synopsis of all cases of uterus transplantation (UTx) that has been published and technical details about surgery. The live births that so far have been reported are described regarding pregnancy and outcome. In addition, the review highlights some specific areas of live donor UTx, deceased donor UTx and UTx in general that need further research for clarification/optimization. It is predicted that the clinical field of UTx will expand rapidly and recommendations for a scientific development of the UTx field are presented. Recent findings The first successful UTx wa...
Uterus transplantation (UTx) is an option for women with uterine factor infertility to achieve motherhood. Since the first live birth in 2014 in Sweden, the demand for this novel therapy has been expanding around the world. While living donors have largely met the current demand, it is projected that donor availability will rapidly become limited as this experimental therapy becomes standard of care. There is thus a great need to quantify the pool of potential deceased uterus donors. This knowledge is necessary not only to guide centers starting uterus transplant programs but ultimately to inform donor and recipient select...
The decidua is a transient uterine tissue shared by mammals with hemochorial placenta and is essential for pregnancy. Hoxa11 knockout (KO) mice are infertile having endometrial stromal cell defects resulting in lack of decidualization and implantation failure. Since bone marrow (BM)-derived cells (BMDC) were shown to differentiate into non-hematopoietic endometrial cells, we hypothesized that bone marrow transplantation from wild-type (WT) mice may rescue uterine defects in Hoxa11 KO mice.
Uterus transplantation (UTx) is an evolving curative therapy for uterine factor infertility (UFI). While live births have been achieved at a handful of centers around the world, estimating the need for UTx is essential prior to expansion of this innovative therapy. Reports from uterine transplant programs at Baylor University Medical Center at Dallas and Cleveland Clinic Foundation suggest great interest in UTx from the community. The purpose of this study was to quantify and characterize candidacy and interest in UTx at a high-volume transplant center in the Northeast.
ConclusionThe majority of respondents in a sample of US residents support UTx, find it ethical, and believe that it is an acceptable alternative to a gestational carrier although support varies. These findings suggest that the US public is in favor of uterine transplantation as a treatment for uterine factor infertility.
ConclusionJust under half of the reproductive endocrinologists and minimally invasive surgeons surveyed find uterine transplantation to be an ethical option for patients with AUFI. Important concerns remain regarding the risk to donors, recipients, and resulting infants, all contributing to only a minority currently recommending it as a therapeutic option.